Numerous US Approvals Received By Lupin Following 278% Quarterly Profits Raise
Analysts Posit That Lupin Has Peaked For The Year
Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.
You may also be interested in...
Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat.
The performance of its recently-launched Spiriva generic will be crucial for Lupin’s future performance, as it forecasts year-end exit margins in the high teens.
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.